5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BRAF mutation predicts MEK-dependence in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Pratilas, C. A.; Halilovic, E.; Persaud, Y.; Sawai, A.; Grbovic-Huezo, O.; Janakiraman, M.; Rosen, N.; Solit, D. B.
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save
  • Economic evaluation of sunitinib vs. interferon-alfa (IFN-alpha) in first-line metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Negrier, S.; Remak, E.; Brown, R.; Kim, S. T.; Charbonneau, C.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated efficacy and safety results and further analysis of prognostic factors
    Meeting Abstract

    Motzer, R. J.; Michaelson, M. D.; Hutson, T. E.; Tomczak, P.; Bukowski, R. M.; Rixe, O.; Negrier, S.; Kim, S. T.; Chen, I.; Figlin, R. A.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): Phase 2 trial
    Meeting Abstract

    Modi, S.; Stopeck, A.; Kinden, H.; Sugarman, S.; Ma, W.; Solit, D.; Kersey, K.; Johnson, R.; Hannah, A. L.; Hudis, C.
    Breast Cancer Research and Treatment (2007)

    Fulltext@MSK | Save
  • Sunitinib plus interferon-alfa in the first-line treatment for metastatic renal cell carcinoma (mRCC): Results of a dose-finding study
    Meeting Abstract

    Kondagunta, G. V.; Hudes, G.; Figlin, R.; Wilding, G.; Hariharan, S.; Kempin, S.; Fayyad, R.; Hoosen, S.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure-response for sunitinib in metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Houk, B. E.; Bello, C. L.; Michaelson, M. D.; Bukowski, R. M.; Redman, B.; Hudes, G. R.; Wilding, G.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Sunitinib in patients with cytokine-refiractory metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    George, D. J.; Michaelson, M. D.; Rosenberg, J. E.; Redman, B. G.; Hudes, G. R.; Bukowski, R. M.; Kim, S. T.; Chen, I.; Wilding, G.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC)
    Meeting Abstract

    Gallagher, D. J.; Milowsky, M. I.; Gerst, S. R.; Iasonos, A.; Boyle, M.; Riches, J.; Bajorin, D. B.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Circulating tumor cells as prognostic biomarkers in patients with metastatic prostate cancer
    Meeting Abstract

    Danila, D. C.; Heller, G.; Leversha, M. A.; Lilja, H.; Gonzalez-Espinoza, R.; Anand, A.; Larson, S.; Schwartz, L. H.; Fleisher, M.; Scher, H. I.
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQOL) and kidney cancer-related symptoms in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib versus interferon (IFN)-alfa: results for European and US subsample analyses in a randomized, multinational phase III trial
    Meeting Abstract

    Cella, D.; Li, J. Z.; Bushmakin, A. G.; Cappelleri, J. C.; Kim, S. T.; Chen, I.; Charbonneau, C.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save